KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Total Non-Current Liabilities (2018 - 2026)

TherapeuticsMD filings provide 11 years of Total Non-Current Liabilities readings, the most recent being $9.7 million for Q1 2026.

  • On a quarterly basis, Total Non-Current Liabilities fell 9.03% to $9.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $9.7 million, a 9.03% decrease, with the full-year FY2025 number at $9.9 million, down 7.48% from a year prior.
  • Total Non-Current Liabilities hit $9.7 million in Q1 2026 for TherapeuticsMD, down from $9.9 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $272.7 million in Q1 2022 to a low of $9.7 million in Q1 2026.
  • Median Total Non-Current Liabilities over the past 5 years was $12.8 million (2024), compared with a mean of $50.6 million.
  • Biggest five-year swings in Total Non-Current Liabilities: tumbled 90.29% in 2023 and later dropped 7.48% in 2025.
  • TherapeuticsMD's Total Non-Current Liabilities stood at $54.2 million in 2022, then plummeted by 75.31% to $13.4 million in 2023, then dropped by 20.01% to $10.7 million in 2024, then decreased by 7.48% to $9.9 million in 2025, then decreased by 1.74% to $9.7 million in 2026.
  • The last three reported values for Total Non-Current Liabilities were $9.7 million (Q1 2026), $9.9 million (Q4 2025), and $10.4 million (Q3 2025) per Business Quant data.